Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 4Ureteral Neoplasms 3Urologic Neoplasms 2Urethral Neoplasms 2Carcinoma, Transitional Cell 2Urothelial Cancer 1Metastatic Urothelial Cancer 1

Interventions

enfortumab vedotin 4pembrolizumab 2Gemcitabine 2Cisplatin 2vinflunine 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1durvalumab 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1avelumab 1adavosertib 1X-Rays 1Trastuzumab 1Surgical Procedures, Operative 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × Urinary Bladder Neoplasms × enfortumab vedotin × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03924895 2025-08-28

KEYNOTE-905

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
595 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms

NCT03219333 2024-08-27

EV-201

Astellas Pharma Inc

Phase 2 Completed
219 enrolled 32 charts 2 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡